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Abstract
Background: Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by a 
spectrum of clinical manifestations, immunological abnormalities, and varied laboratories results. 
In children, SLE manifestation is particularly more severe, involving more organs. Hematological 
manifestation has been known as the most common manifestation. The purpose of this study was 
to describe the clinical manifestations and hematologic interpretation of pediatric SLE at initial 
presentation.
Methods: This retrospective data collection study was conducted at the Department of Child Health 
Dr. Hasan Sadikin General Hospital Bandung on medical records from a two-year period of 2017–
2018. The clinical manifestations were categorized into malar rash, discoid rash, photosensitivity, 
oral ulcers, arthritis, renal disorders, and neurological disorders. The hematologic interpretations 
were categorized into anemia, leukopenia, neutropenia, lymphopenia, and thrombocytopenia. Clinical 
manifestations and hematological interpretations were presented as occurrence percentages and 
stratified into three age-group of pre-pubertal, peri-pubertal, and post-pubertal. 
Results: Among 79 pediatric SLE patients (median age 14 years old; IQR 11–16), female gender was 
predominant. Abnormalities hematologic interpretation occurs in more than half of the patients 
(83.5%). Malar rash and anemia were the commonest findings among all age groups. Increased 
occurrence of neuropsychiatric and renal disorders were observed in all age-groups.
Conclusions: Malar rash and anemia are important findings among pediatric SLE patients. 
Furthermore, the occurrences of the neuropsychiatric and renal disorders are also important. 
Keywords: Hematologic interpretation, neuropsychiatric, renal disorder, pediatric, systemic lupus  
       erythematosus
Introduction
Systemic Lupus Erythematosus (SLE) is a 
complex multi-system autoimmune illness 
characterized by a broad spectrum of clinical 
manifestations, with immunological and 
laboratory abnormalities. It can affect all 
people of both genders and various races/
ethnicities, age groups, socioeconomic status, 
and others. The incidence of SLE in the world 
has reached 0.3–23.7 per 100,000 population 
per year.1 The prevalence of SLE in the Asia 
Pacific is 0.9–3.1 per 100,000 populations 
per year. In addition, lupus is also considered 
an illness that has a fairly high mortality 
rate. In 2016, the Indonesian Ministry of 
Health reported a high mortality number of 
hospitalized lupus patients which was 550 out 
of 2,166 patients.2
Pediatric SLE is defined as a systemic 
autoimmune disease whose symptoms 
occur before the age of 18.3 The occurrence 
of pediatric SLE is about 10–20% of total 
SLE cases, with an incidence of 0.3–0.9 per 
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100,000 children per year. The previous 
study has reported that children-onset has 
more diverse and heavier manifestation.1,4 
Hematologic abnormality is one of the most 
common manifestations of SLE in children with 
approximately 50% of cases. Abnormalities 
hematologic interpretation in SLE consists of 
leukopenia, with lymphopenia, neutropenia, 
or both; anemia and thrombocytopenia.4-8 
Therefore, the hematology examination is 
one of the most frequent examinations and 
criteria for identifying SLE patients based 
on the American College of Rheumatology 
(ACR) 1997 and The Systemic Lupus 
International Collaborating Clinics (SLICC) 
2012.7,9,10 Children growth period contribute 
to the severity of pediatric SLE.1 Therefore, the 
identification of pediatric SLE becomes more 
challenging.
Dr. Hasan Sadikin General Hospital, as our 
study site, is a tertiary hospital, located in 
the West Java Province, admitting pediatric 
SLE patients with approximately 249 cases 
annually. A limited study has been done 
to identify the clinical manifestation and 
hematologic result among pediatric SLE at this 
population level, particularly for age-group in 
the children growth period. This study was 
conducted to have a better understanding of 
the clinical manifestation and hematologic 
interpretation of pediatric SLE at initial 
presentation.
Methods
This was a descriptive study with retrospective 
data, collected from patient medical records 
from 1 January 2017 to 31 December 2018. 
These two years period study was conducted 
at the Department of Child Health Dr. Hasan 
Sadikin General Hospital Bandung. This study 
retrieved and screened medical records for 
outpatient and inpatient according to the ICD-
10 diagnosis of Systemic Lupus Erythematosus 
(ICD-10-CM Codes M32*). Screened data were 
selected based on inclusion and exclusion 
criteria. The inclusion criteria of this study 
were pediatric patients (<18 years) with 
SLE based on ACR and SLICC3,10 who had 
complete hematologic examination such 
as hemoglobin, leukocytes, neutrophils, 
lymphocytes, platelets, and hematocrit at the 
time of initial diagnosis. The exclusion criteria 
were incomplete and unclear information data 
written in the medical record and an irregular 
routine visits to the hospital. 
The variables used in this study were 
age, gender, and clinical manifestations that 
were categorized as malar rash, discoid 
rash, photosensitivity, oral ulcers, arthritis, 
renal disorders, and neurological disorders. 
Furthermore, data on hematology results, 
including hemoglobin levels, erythrocyte index 
i.e. MCV, MCH, MCHC, number of leukocytes, 
neutrophils, lymphocytes, and platelets were 
retrieved. The hematologic interpretation 
was defined and categorized into: anemia, 
leukopenia, neutropenia, lymphopenia, and 
thrombocytopenia. Anemia was designated 
as hemoglobin level <11g/dl for children aged 
6–59 months, <11.5d/dl for aged 5–11 years, 
and <12 d/dL for aged >11 years; Leukopenia 
was designated as leukocytes level <4,000/
mm3, neutropenia as neutrophils level 
<1,000/mm3, lymphopenia as lymphocytes 
level <1500/mm3, and thrombocytopenia 
as thrombocytes level <150,000/mm3.4,5,8 
To analyze the clinical manifestation and 
hematologic interpretation, we had defined 
age group into three categories based on pre-
pubertal growth period (male of age ≤9 years 
old and female ≤8 years old); peripubertal 
(male of age >9–<14 years old and female > 
8–<13 years old); and post-pubertal (male ≥14 
years old and female ≥ 13 years old).11
General demographic, clinical 
manifestation, and hematologic interpretation 
were presented as frequency, to present 
Table 1 Hematological Values at Initial Presentation of Newly Diagnosed Systemic Lupus 
  Erythematosus Pediatric Patients at the Department of Child Health, Dr. Hasan 
   Sadikin General Hospital Bandung during 2017 and 2018



















Note: IQR= interquartile range
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the overall insight of the data population. 
The stratification with the age group was 
performed to observe the occurrence of clinical 
manifestation and hematologic interpretation 
among the age group category. All the data 
were analyzed using statistical software (IBM 
SPSS ver. 19, Chicago, IL, USA). This study 
was approved by the Ethics Committee of 
Universitas Padjadjaran (No.651/UN6.KEP/
EC/2019) and the Health Research Ethics 
Committee of Dr. Hasan Sadikin General 
Hospital (No.LB.02.01/X.2.2.1/10522/2019). 
Results
A total of 185 data were screened according 
to the ICD-10-CM:M32, however, only 79 data 
fulfilled the inclusion criteria. Characteristics 
of newly diagnosed pediatric SLE patients 
at the Department of Child Health, Dr. Hasan 
Sadikin General Hospital Bandung between 
1 January 2017 and 31 December 2018 were 
dominated by a female (92.4%) with a ratio 
of male:female was 1:12. The median age 
of the cases was 14 years old (range 11–16 
years). In general, anemia was observed at 
initial presentation among the pediatric SLE 
population (n=61;77.2%). The hematological 
values at the initial presentation were depicted 
in Table 1.
Based on the age group of pediatric SLE, 
the most common clinical manifestation 
at the onset of disease was malar rashes, 
which was found in the range 20–30% of all 
age-group. Photosensitivity was the second 
common clinical manifestation among the pre-
pubertal and post-pubertal groups, 25%, and 
23.3%, respectively. The renal disorders and 
discoid rashes were more likely to be found 
as a second clinical manifestation in the peri-
pubertal group. The interesting findings were 
the increased trend of neurologic disorders 
occurrence and renal disorders among age-
group (Figure 1).
The occurrence of anemia was the most 
common hematological manifestation 
among all the age-group, ranging between 
37.5–46%. Lymphopenia, with or without 
Figure 1 Clinical Manifestations of Pediatric Systemic Lupus Erythematosus Patients based 
    on Age Group
Note: n=number of clinical manifestations frequency observed in 79 patients, which can have 
more than one clinical manifestation
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leukopenia was observed as the second 
frequent hematological manifestation in peri-
pubertal and post-pubertal, 27% and 32.6%, 
respectively. Meanwhile, the occurrence 
of thrombocytopenia was found more 
frequent in pre-pubertal (25%). Among all 
the hematological manifestations, such as 
anemia with thrombocytopenia, anemia with 
lymphopenia, or anemia, leukopenia and 
lymphopenia, were a frequent combination 
of hematological manifestations among the 
pediatric SLE populations (Figure 2).
Discussion
This study shows the initial presentation 
of clinical manifestation and hematologic 
interpretation of pediatric SLE, which is 
important to the identification of SLE. In 
this study, the clinical manifestations from 
pediatric SLE are very diverse, both in terms 
of numbers and types of abnormalities. 
Malar rashes are the most common clinical 
manifestation in all age groups category within 
this study. This finding is similar to the previous 
report, which observes mucocutaneous 
disorder, especially malar rashes, occurs in 
almost every case of SLE.12 The main cause 
of the malar rash is UV light that stimulates 
keratinocytes to produce innate cytokine and 
trigger cell death, and promote inflammatory 
infiltrates which damage skin tissues.13 Skin 
disorders likely to be the easiest finding to 
recognize and to examine, either by patients 
or by physicians.14 Therefore, the malar rashes 
are the important finding of this study. 
Neuropsychiatric disorders or NPSLE 
and renal disorders are among the causes 
of mortality and morbidity in children with 
SLE.3,15 In this study, the occurrence of NPSLE 
and renal disorder increased among the age 
groups. NPSLE is caused by autoantibody 
production, micro-angiopathy, intrathecal 
production of pro-inflammatory cytokines, 
and premature atherosclerosis that disturb 
the integrity of the blood-brain barrier and 
allow, thus, more proteins or cells access to the 
CNS.15,16 The mechanism of renal disorder is the 
deposition of the antigen-antibody complex 
on glomeruli and promotes inflammation and 
adjacent cell proliferation such as endothelial 
cells, epithelial cells, and mesangial cells.3,4,15 
Figure 2  Hematological Manifestation of Pediatric Systemic Lupus Erythematosus Patients 
     Based on Age Group
Note: n=number of clinical manifestations frequency observed in 79 patients, which can have 
more than one hematological manifestationn
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Although the previous study has shown that 
renal and neuropsychiatric disorders were the 
most commonly found clinical manifestations 
in the pre-pubertal group, however, we observe 
in our current study that the occurrence of 
the renal disorder increases with the age-
group due to complexity of the disease to the 
body metabolism. On the other hand, NPSLE 
is more likely to occur in older age due to 
difficulties observing psychiatric symptoms in 
small children. Moreover, a neuropsychiatric 
disorder is usually found at a follow-up or in 
the first year after the first diagnosis of SLE is 
done. 3,4,15,16
Hematologic abnormalities present as 
high as 83.5% among all pediatric SLE, and 
anemia is the most common abnormality. 
Specific autoantibodies might directly attack, 
opsonize, phagocyte, and lyse erythrocytes, 
leukocytes, and thrombocytes, leading to the 
decreased amount in the blood.17 Anemia is 
generally caused by several factors i.e. low 
erythropoiesis due to low erythropoietin in 
chronic disease; low levels of ferritin, and 
hemolytic anemia. The occurrence of anemia 
reported by other studies is ranging between 
50–70%.6,18 
Leukopenia, with or without lymphopenia 
or neutropenia, and thrombocytopenia are 
also common in pediatric SLE.5,19 Leukopenia 
can be accompanied by lymphopenia, 
neutropenia, or both. Lymphopenia in SLE is 
generally caused by a decreased number of T 
and B lymphocytes due to an increased number 
of natural killer cells, a decreased number of 
proteins that regulate complement, resulting 
in complement-mediated lysis. Furthermore, 
it can be caused by the presence of cytotoxic 
anti-lymphocyte antibodies.5,18 The number 
of pediatric SLE with lymphopenia increases, 
in line with the increase of age when the first 
diagnosis of SLE. Leukopenia can also be caused 
or worsened by the use of immunosuppressant 
drugs that may suppress the bone marrow.5,19 
Thrombocytopenia in SLE is generally caused 
by the increase of platelet destruction and 
the presence of anti-platelet antibodies that 
might attack antigens on the surface of the 
platelet. In addition, similar to leukopenia, 
thrombocytopenia can also be caused by the 
use of immunosuppressant drugs, which can 
interfere with platelet production.5
Limitations of this study are among others 
the small numbers of pediatric SLE cases over 
two years of study, which may lead to an over-
estimated percentage of occurrences among 
the age groups. There is limited information 
in examinations available to determine other 
causes of various hematologic abnormalities. 
Further study recruiting more cases is of great 
interest, therefore, the age-group population 
could be distributed evenly, which can present 
the actual estimated number of occurrence of 
both clinical manifestation and hematologic 
interpretation in pediatric SLE patients.
In conclusion, clinical manifestation and 
hematologic interpretation of pediatric SLE 
patients are important factors. Malar rash 
and anemia are the common findings among 
all age-group of pediatric SLE patients. The 
occurrences of neuropsychiatric and renal 
disorder among age-group are observed as 
important finding in this study. 
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